Mary Linn, PA
Medical · van Buren, ARNPI 1013149798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 383 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$772
- Novo Nordisk$616
- GSK$519
- Amgen$483
- Lilly USA, LLC$410
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,05298%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,203 |
| AstraZeneca(2 entities) | 35 | $772 |
| Novo Nordisk | 30 | $616 |
| GSK | 38 | $519 |
| Amgen | 33 | $483 |
| Lilly USA, LLC | 27 | $410 |
| Pfizer | 20 | $294 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $209 |
| Boehringer Ingelheim | 14 | $205 |
| Otsuka America Pharmaceutical, Inc. | 6 | $132 |
| Exact Sciences | 7 | $131 |
| Sumitomo Pharma America, Inc. | 8 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $130 |
| Biohaven Pharmaceuticals, Inc. | 11 | $125 |
| Astellas Pharma US Inc | 2 | $107 |
| Johnson & Johnson | 7 | $101 |
| Bayer | 6 | $88 |
| Antares Pharma, Inc. | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 5 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Corium, LLC | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Boston Scientific | 1 | $23 |
| Merck | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Tonix Medicines, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$131
- FARXIGA$125
- TRELEGY ELLIPTA$125
- RYBELSUS$122
How this compares
$6,146 in reported general payments places this provider in the 85th percentile of 133 medical providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $34,341 |
| MounjaroTirzepatide | 31 | $31,411 |
| OzempicSemaglutide | 29 | $26,473 |
| XareltoRivaroxaban | 23 | $23,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,332 |
| JanuviaSitagliptin Phosphate | 18 | $15,944 |
| JardianceEmpagliflozin | 16 | $9,746 |
| MyrbetriqMirabegron | 21 | $9,408 |
| FarxigaDapagliflozin Propanediol | 15 | $8,357 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,294 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,841 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,390 |
| Novolog FlexpenInsulin Aspart | 13 | $4,316 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 194 | $3,793 |
| Dexlansoprazole DrDexlansoprazole | 15 | $2,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $294 | $34,34140 claims |
| Lilly USA, LLCMounjaro | $410 | $31,41131 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $772 | $31,07961 claims |
| Novo NordiskOzempic | $616 | $26,47329 claims |
| Johnson & JohnsonXarelto | $101 | $23,29723 claims |
| MerckJanuvia | $23 | $15,94418 claims |
| Boehringer IngelheimJardiance | $205 | $9,74616 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $9,40821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 medical providers in Arkansas.
Other medical in van Buren
- Matthew ReynoldsRussellville$207K
- Tara BrunerSearcy$16K
- Dallas BondhusHot Springs$15K
- Douglas ClarkLittle Rock$14K
- Alexandra SanromaLittle Rock$11K
- Caleb MasonSearcy$9K
- Katherine McCradyLittle Rock$9K
- Bailey PollockLittle Rock$9K
- Hannah BreauLittle Rock$9K
- Thurman SmithFayetteville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.